Decision: Favourable

Study Title:

Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach to curative-intent treatment – SHAMROCK study

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    MD Application

  • Principal Investigator:

    Prof. Bryan Hennessy

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Cancer Trials Ireland

Scroll to Top